Amalya Sargsyan, Medical Oncologist at Yeolyan Hematology and Oncology Center, shared on X:
“FLOT + Durvalumab is now part of the NCCN guidelines for treating resectable gastric and GEJ tumors based on MATTERHORN trial led by Yelena Y. Janjigian
Some people don’t just save lives, they change the way others do it. This is what truly inspires and motivates.”
Arturo LoAIza-Bonilla, Co-founder at Massive Bio, shared Amalya Sargsyan’s post on X:
“Thank you National Comprehensive Cancer Network (NCCN) for the real time updates and decision support so we can help our patients. Using this and the NEJM paper by Yelena Y. Janjigian et al. was able to add it to a patient just this week!”
More posts featuring Gastric Cancer.